Medtronic (MDT) to Announce Earnings on Tuesday

Medtronic (NYSE:MDT) is expected to post its Q1 2027 results before the market opens on Tuesday, September 1st. Analysts expect the company to announce earnings of $1.39 per share and revenue of $9.5458 billion for the quarter. Medtronic has set its FY 2027 guidance at 5.900-6.000 EPS. Investors are encouraged to explore the company’s upcoming Q1 2027 earning report page for the latest details on the call scheduled for Tuesday, September 1, 2026 at 7:45 AM ET.

Medtronic (NYSE:MDT) last posted its quarterly earnings data on Wednesday, June 3rd. The medical technology company reported $1.55 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.54 by $0.01. Medtronic had a net margin of 13.20% and a return on equity of 14.51%. The firm had revenue of $9.81 billion for the quarter, compared to the consensus estimate of $9.62 billion. During the same period in the previous year, the firm earned $1.62 EPS. The business’s revenue for the quarter was up 9.9% compared to the same quarter last year. On average, analysts expect Medtronic to post $6 EPS for the current fiscal year and $6 EPS for the next fiscal year.

Medtronic Stock Performance

NYSE MDT opened at $91.28 on Friday. The company has a fifty day moving average price of $85.57 and a 200-day moving average price of $85.67. The firm has a market cap of $116.84 billion, a price-to-earnings ratio of 24.47, a PEG ratio of 2.45 and a beta of 0.55. The company has a debt-to-equity ratio of 0.52, a current ratio of 2.13 and a quick ratio of 1.62. Medtronic has a 1 year low of $73.31 and a 1 year high of $106.33.

Medtronic Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, October 16th. Investors of record on Friday, September 25th will be issued a dividend of $0.72 per share. The ex-dividend date is Friday, September 25th. This represents a $2.88 annualized dividend and a yield of 3.2%. Medtronic’s payout ratio is 77.21%.

Insider Transactions at Medtronic

In other Medtronic news, EVP Harry Skip Kiil sold 4,189 shares of Medtronic stock in a transaction dated Monday, June 8th. The shares were sold at an average price of $80.44, for a total value of $336,963.16. Following the sale, the executive vice president owned 37,227 shares of the company’s stock, valued at approximately $2,994,539.88. The trade was a 10.11% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Company insiders own 0.27% of the company’s stock.

Institutional Investors Weigh In On Medtronic

Several large investors have recently modified their holdings of MDT. Brighton Jones LLC grew its position in shares of Medtronic by 1,368.0% during the 4th quarter. Brighton Jones LLC now owns 39,989 shares of the medical technology company’s stock valued at $3,194,000 after purchasing an additional 37,265 shares in the last quarter. Sivia Capital Partners LLC raised its position in shares of Medtronic by 9.6% in the second quarter. Sivia Capital Partners LLC now owns 4,356 shares of the medical technology company’s stock worth $380,000 after buying an additional 381 shares in the last quarter. DV Equities LLC bought a new stake in Medtronic during the fourth quarter valued at $171,000. Resources Management Corp CT ADV grew its position in Medtronic by 360.0% during the fourth quarter. Resources Management Corp CT ADV now owns 575 shares of the medical technology company’s stock worth $55,000 after buying an additional 450 shares in the last quarter. Finally, Quarry LP purchased a new position in Medtronic during the fourth quarter worth about $83,000. Hedge funds and other institutional investors own 82.06% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts have issued reports on MDT shares. Jefferies Financial Group reaffirmed a “hold” rating and issued a $88.00 price objective on shares of Medtronic in a research report on Thursday, June 4th. Stifel Nicolaus set a $80.00 target price on shares of Medtronic in a research report on Wednesday, June 3rd. Royal Bank Of Canada restated an “outperform” rating and issued a $118.00 target price on shares of Medtronic in a research note on Thursday, June 4th. TD Cowen upped their target price on Medtronic from $100.00 to $110.00 and gave the company a “buy” rating in a report on Friday. Finally, Deutsche Bank Aktiengesellschaft decreased their price target on Medtronic from $100.00 to $78.00 and set a “hold” rating for the company in a research report on Thursday, June 4th. Eighteen equities research analysts have rated the stock with a Buy rating and nine have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $99.79.

Trending Headlines about Medtronic

Here are the key news stories impacting Medtronic this week:

• Positive Sentiment: Needham raised its price target to $114 from $101 and reiterated a “Buy” rating, implying substantial upside from recent trading levels. The firm reportedly expects Medtronic to beat first-quarter estimates and raise its fiscal 2027 guidance. Needham raises Medtronic price target
• Positive Sentiment: Analysts see potential for Medtronic to exceed consensus first-quarter expectations of approximately $1.39 in adjusted EPS and $9.54 billion in revenue. A stronger-than-expected report could support the shares, particularly if management lifts its fiscal 2027 outlook. Medtronic earnings estimates
• Positive Sentiment: Recent coverage highlights momentum in Medtronic’s cardiovascular businesses and growth in renal denervation, while broader device demand is supporting the company’s rebound narrative. Medtronic device momentum
• Neutral Sentiment: The imminent earnings release is likely to keep volatility elevated. Investors will evaluate quarterly performance, procedure trends, and management’s fiscal 2027 guidance for confirmation that the recovery is sustainable. Medtronic rebound outlook
• Negative Sentiment: Tariff exposure and unfavorable currency movements remain potential headwinds to margins and reported growth. These risks could limit the benefit of strong cardiovascular trends or weigh on the shares if management issues cautious guidance. Medtronic portfolio outlook

Medtronic Company Profile

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).